Resources
98 Results (showing 61 - 70)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/21/2023 (updated 3/28/2024)
Posted 6/22/2023 (updated 3/28/2024)
The Buncombe Bridge to Care (BB2C): Post-Overdose Buprenorphine Field Initiation Program Toolkit was developed by Buncombe County Emergency Services Community Paramedicine and UNC Health Sciences at Mountain Area Health Education Center (MAHEC). This toolkit describes the project and protocols utilized. It is not intended to be a comprehensive guide or manual, but instead to inspire communities to increase access to lifesaving medication for the marginalized community of people who use drugs.
Posted 6/22/2023 (updated 3/28/2024)
The Practical Guide for Implementing a Trauma-Informed Approach was developed by SAMHSA. The guide focuses on tools and strategies for implementing a Trauma-Informed Approach across ten domains.
Posted 6/13/2023 (updated 3/28/2024)
Tribal communities throughout the United States are often acknowledged as having higher rates of negative health outcomes, including higher rates of overdose and substance use, with little context given to the contributing historical and contemporary factors.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.
Posted 3/7/2023 (updated 3/27/2024)
n December 2022, Congress eliminated the DATA-Waiver program registration allowing providers to prescribe buprenorphine to treat patients for OUD. The University of Vermont Center on Rural Addiction, a HRSA Rural Center of Excellence on Substance Use Disorders, offers an incentive to help defray previous training costs of $750 to each qualifying provider who obtained a DATA-Waiver. To qualify, providers must be practicing in a HRSA-designated rural county in Vermont, Maine, New Hampshire, or Northern New York.
Posted 1/24/2023 (updated 3/27/2024)
Clinicians no longer need DATA 2000 Waiver training to prescribe buprenorphine; however, the payment program to defray earlier training costs is still active. Launched in June 2021, the initiative pays for providers who previously received a waiver to prescribe buprenorphine, a medication used to treat opioid use disorder. Rural Health Clinics (RHCs) still have the opportunity to apply for a $3,000 payment on behalf of each provider who previously trained to obtain the waiver necessary to prescribe buprenorphine after January 1, 2019.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 6/8/2023 (updated 3/27/2024)
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD) with a relatively low rate of triggering precipitated withdrawal in patients. Increased precipitated withdrawal rates have become a concern for practitioners in emergency departments when treating with buprenorphine with the prevalence of fentanyl in the drug supply.